also developing our product candidate Zimura, with an initial focus on the treatment of geographic atrophy, a severe form of dry AMD, and expect to initiate a Phase 2/3 clinical trial of Zimura
2012, we completed a large Phase 2b clinical trial in newly diagnosed wet AMD patients in which 1.5 mg of Fovista administered in combination with one of the standard of care drugs, Lucentis,
For example, based on results of third-party clinical trials, after one year of treatment with an anti-VEGF drug, approximately 18% to 22% of newly diagnosed wet AMD patients lost
Phase 3 clinical program evaluating Fovista administered in combination with anti-VEGF drugs for the treatment of newly diagnosed wet AMD patients.
also plan to initiate in 2015 a Phase 2 clinical trial evaluating the safety and efficacy of Zimura and Fovista administered in combination with an anti-VEGF drug in anti-VEGF resistant wet AMD
evaluate the potential of Fovista in wet AMD, when administered in combination with anti-VEGF drugs, and in other ophthalmic diseases and conditions with unmet need; to fund a Phase 2/3 clinical trial evaluating Zimura for the treatment of
geographic atrophy, a severe form of dry AMD, and a Phase 2 clinical trial evaluating Zimura and Fovista administered in combination with an anti-VEGF drug for the treatment of certain wet AMD patients; and for working capital and other general
receive, or expect to receive, marketing approval for any of our product candidates;•maintain, expand and protect our intellectual property portfolio;•hire additional clinical, quality control and scientific personnel; and•add operational, financial and management information systems and personnel, including personnel to support our clinical,
studies in addition to those we currently expect to conduct, or if there are any delays in completing the clinical trials of Fovista or Zimura, or the development of any of our other product
If we obtain marketing approval for Fovista, Zimura or any other product candidate that we develop, we expect to incur significant commercialization expenses related to product sales, marketing,
of Fovista in wet AMD, when administered in combination with anti-VEGF drugs, and in other ophthalmic diseases and conditions with unmet need, an additional planned clinical trial evaluating Zimura
Fovista in wet AMD, when administered in combination with anti-VEGF drugs, and in other ophthalmic diseases and conditions with unmet need;•the scope, progress, results and costs of our planned Phase 2/3 clinical trial evaluating Zimura for the treatment of
addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans.16Table of ContentsIf we fail to enroll patients in our Phase 3 clinical trials of Fovista as planned or fail to comply with our obligations in our royalty agreement with
initial results from our planned Phase 2 clinical trial of Zimura and Fovista administered in combination with an anti-VEGF drug until 2016.
of dry AMD or the use of Zimura administered in combination with Fovista and anti-VEGF drugs for the treatment of wet AMD;•the scope of the label that may be approved by applicable regulatory authorities, including the specific indication for
Fovista will be used;•effectively competing with other therapies, including the existing standard of care, and other forms of drug delivery;•maintaining a continued acceptable safety profile of the product candidate following approval;•obtaining and maintaining patent and trade secret protection and regulatory exclusivity; and•protecting our rights in our intellectual property portfolio.Successful
United States to require additional clinical trials or other research before granting marketing approval of Fovista for use in combination with any anti-VEGF drug, including Lucentis, for the
In addition, we have no clinical data on the effects of Zimura when administered in combination with both Fovista and an anti-VEGF drug.Even if Fovista, Zimura or any other product candidate that we develop receives marketing approval, it may fail to achieve the degree of market acceptance by physicians,
development or marketing approval of our product candidates or commercialization of our products, producing additional losses and depriving us of potential product revenue.We contract with third parties for the manufacture of both Fovista and Zimura for clinical trials and expect to continue to do so in connection with the commercialization of